Researchers from Oregon Health and Science University (OHSU) are seeking patent protection for a transcervical delivery device that may provide clinicians with a simple, inexpensive office-based procedure for the assessment of tubal patency or delivery of a permanent contraceptive agent to the fallopian tube.
In a potential godsend for women struggling with infertility and painful periods, Hera Biotech Inc. acquired the endometriosis diagnostic assets of Scailyte AG, consolidating the two leading tissue-based diagnostic programs for the disease. The combination of the companies’ non-surgical diagnostic options could significantly speed time to treatment for millions of women, who on average spend 10 years in search of the cause of chronic pelvic pain before being diagnosed with endometriosis.
Listening to conversations between a mother and her unborn child on the cellular level could inform how the pregnancy is going and prevent complications. Three scientific groups from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), in collaboration with Wayne State University and Michigan State University, have used single-cell RNA sequencing techniques to decipher these words, identify the cellular language of these interactions in the placenta and establish a cellular atlas.
With the use of 3D printing and microfluidics, Fertilis Pty Ltd. hopes to triple the success rates of in vitro fertilization (IVF) by improving embryo quality and quantity.
Royal Philips NV received a second round of funding from the Bill & Melinda Gates Foundation to speed adoption of artificial intelligence (AI) algorithms on the Lumify hand-held ultrasound device, bringing its total commitment to the project designed to reduce maternal mortality to $60 million.
Femasys Inc. received U.S. FDA 510(k) clearance for Femaseed, an infertility treatment that delivers sperm directly to the fallopian tubes. Less invasive and more straightforward than in vitro fertilization, the procedure offers what the company said is a new and more affordable alternative to family building for couples encountering fertility issues.
Choosing blastocysts for transfer based on size could give prospective parents a much better chance of success in welcoming a new member to the family, a study published in the Nature portfolio journal Scientific Reports demonstrates.
Celmatix Inc. and Aché Laboratórios Farmacéuticos SA will study the role of melatonin receptors and their agonists in polycystic ovary syndrome (PCOS). The two companies announced a collaboration, with a separate license and development agreement upon conclusion of the research.
RSS
